First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review

Arteen Arzivian; Eva Zhang; Robyn Laube; Rupert Leong

doi:10.1002/ccr3.8764

First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review

Arteen Arzivian, Eva Zhang, Robyn Laube, Rupert Leong

Research output: Contribution to journal › Article › peer-review

4 Downloads (Pure)

Abstract

Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real-world data that assists decision-making for future patients.

Original language	English
Article number	e8764
Pages (from-to)	1-4
Number of pages	4
Journal	Clinical Case Reports
Volume	12
Issue number	4
DOIs	https://doi.org/10.1002/ccr3.8764
Publication status	Published - Apr 2024

Bibliographical note

Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

Janus kinase inhibitors
Case report
Inflammatory bowel diseases
Pregnancy
Tofacitinib
Ulcerative colitis

Access to Document

10.1002/ccr3.8764Licence: CC BY

Publisher version (open access)Final published version, 433 KBLicence: CC BY

Cite this

@article{7d1161b803024d998e1cee5e24ec92d8,

title = "First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review",

abstract = "Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real-world data that assists decision-making for future patients.",

keywords = "Janus kinase inhibitors, Case report, Inflammatory bowel diseases, Pregnancy, Tofacitinib, Ulcerative colitis",

author = "Arteen Arzivian and Eva Zhang and Robyn Laube and Rupert Leong",

note = "Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2024",

month = apr,

doi = "10.1002/ccr3.8764",

language = "English",

volume = "12",

pages = "1--4",

journal = "Clinical Case Reports",

issn = "2050-0904",

publisher = "Wiley-Blackwell, Wiley",

number = "4",

}

TY - JOUR

T1 - First-trimester exposure to tofacitinib in ulcerative colitis

T2 - a case report of a healthy newborn and literature review

AU - Arzivian, Arteen

AU - Zhang, Eva

AU - Laube, Robyn

AU - Leong, Rupert

N1 - Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2024/4

Y1 - 2024/4

N2 - Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real-world data that assists decision-making for future patients.

AB - Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real-world data that assists decision-making for future patients.

KW - Janus kinase inhibitors

KW - Case report

KW - Inflammatory bowel diseases

KW - Pregnancy

KW - Tofacitinib

KW - Ulcerative colitis

U2 - 10.1002/ccr3.8764

DO - 10.1002/ccr3.8764

M3 - Article

C2 - 38617066

SN - 2050-0904

VL - 12

SP - 1

EP - 4

JO - Clinical Case Reports

JF - Clinical Case Reports

IS - 4

M1 - e8764

ER -